Choosing an Agentic AI Platform for Pharma: What Should You Evaluate?

Infiligence’s perspective on evaluating agentic AI through intended use, governance, and evidence.

At Infiligence, our work in AI governance and AI-assisted validation centers on a practical question: what must an organization demonstrate before allowing AI to support or act within a regulated workflow? We bring that engineering and validation perspective to platform evaluation, looking beyond model capabilities to examine controls, traceable evidence, and accountable operational ownership.

When evaluating an agentic AI platform for pharma GxP validation, start with the work rather than the model. Are you generating draft test cases, analyzing sales performance, retrieving approved documents, or taking actions in a quality system? These activities need different evaluation criteria and different boundaries on autonomy.

Two questions are often confused: Can AI help produce validation evidence? And has the AI-enabled system been adequately evaluated for its intended use? A tool that drafts a validation protocol does not validate its own output or the surrounding workflow.

A useful starting point is the FDA–EMA guiding principles of good AI practice in drug development. These emphasize a clear context of use, a risk-based approach, multidisciplinary expertise, data governance, performance assessment, and lifecycle management. They are guiding principles and are not to be considered as a product certification or a substitute for applicable requirements. [1]

How to use this guide: Regulatory documents explain obligations and expectations; research papers inform evaluation design; vendor documentation describes advertised capabilities. None of these alone establishes that a particular deployment is validated. The platform comparison below is an evaluation framework, not a hands-on benchmark or endorsement.

In This Guide

• GxP meaning and AI scope
• Validation questions before deployment
• Part 11 controls
• Platform evaluation
• Commercial analytics
• Validation documents and digital archives
• Vendor scorecard
• Governed implementation

What Does GxP Mean in Pharma, and Where Does AI Fit?

The meaning of GxP in pharma is a family of “good practice” disciplines rather than one regulation. The MHRA identifies Good Clinical Practice, Good Distribution Practice, Good Laboratory Practice, Good Manufacturing Practice, and Good Pharmacovigilance Practice within this umbrella. The applicable framework depends on the activity and jurisdiction. [2]

When buyers use the phrase “GxP company,” they should ask a more precise question: which activities, systems, services, and evidence fall within that supplier’s quality framework? Do not treat a general company description as evidence that every product or AI workflow meets every applicable requirement.

For procurement, separate proposed use cases before comparing vendors:

These are planning examples, not regulatory classifications. Quality and regulatory specialists should determine the actual GxP impact. A commercial label does not automatically remove risk, and an AI label does not automatically place every output within Part 11.

GxP AI Validation: Questions to Ask Before Deployment

AI validation in pharma should examine the configured system and its workflow and not just the underlying language model. For an agent, that evaluation boundary may include retrieval, prompts, tools, permissions, source systems, user interfaces, and human approvals.

EU GMP Annex 11, currently the January 2011 revision, states that the application should be validated and the supporting IT infrastructure should be qualified. For computerised systems used in GMP-regulated activities, it links the extent of validation and control to documented risk assessment, user requirements, supplier/service-provider assessment, testing, and change/configuration management. [3]

1. What Is the Intended Use—and What Is Explicitly Excluded?

Define users, inputs, outputs, permitted actions, and consequences of failure. “Improve regulatory productivity” is too broad. “Draft a requirements-to-test mapping from approved documents for qualified review, without approving or modifying source records” is an evaluable scope.

The FDA’s January 2025 draft guidance proposes a risk-based credibility framework for AI producing information or data to support drug regulatory decision-making. Its context-of-use approach is relevant to evaluation planning, but the FDA page labels it draft, not for implementation, and nonbinding. It is not a blanket validation standard for every enterprise AI use case. [4]

2. What Evidence Demonstrates Useful Performance?

Build a held-out test set from representative, appropriately authorized material. Include difficult examples: conflicting versions, incomplete requirements, tables, long documents, unusual terminology, and questions with no supported answer. Define acceptance criteria before vendors see the test set.

Research evidence: Wornow and colleagues reviewed 84 foundation models trained on non-imaging electronic medical record data and identified a disconnect between commonly used evaluations and usefulness to health systems. Their 2023 review supports measuring outcomes relevant to the deployment and not relying on a generic benchmark score. It does not compare current pharma platforms or establish their validation status. [5]

3. Does Performance Hold Across Repeated Runs and Document Variations?

Repeat representative tasks, record the configuration, and report variability instead of just using the best response. Test the same facts in different document positions and formats. Measure unsupported statements, critical omissions, citation correctness, appropriate abstention, and completion of permitted actions.

Research evidence: Liu and colleagues’ peer-reviewed study, Lost in the Middle, found that the models studied often performed worse when relevant information appeared in the middle of long contexts. A large advertised context window therefore should not replace testing of document retrieval and evidence use. This is a historical finding about the evaluated models, not proof that every current model fails in the same way. [6]

4. Can You Control Changes and Investigate Failures?

Ask vendors to demonstrate version identification, update notice, supported rollback or fallback options, and exportable execution records. Your change assessment should consider model replacements, prompt revisions, retrieval-index updates, connector changes, and permission changes. Identical wording on every rerun is not the only possible acceptance criterion; what matters is documented, acceptable performance within the defined use.

For multi-agent proposals, require a simpler baseline. A 2025 research preprint, Towards a Science of Scaling Agent Systems, found that coordination benefits depended on task and architecture under controlled computational budgets. It is useful evidence against assuming that more agents always improve performance, but it is not peer-reviewed pharma validation evidence. [7]

Evaluating AI Controls Against 21 CFR Part 11 Requirements

“21 CFR Part 11 AI compliance” is useful for search shorthand, but the regulation addresses electronic records and electronic signatures, and is not a special certification for AI models. FDA’s guidance explains that applicability turns on electronic records required by predicate rules, records submitted electronically to FDA, and relevant electronic signatures. Document the applicability decision before creating a control checklist. [8]

The regulatory mapping above comes from the text of Section 11.10. FDA’s scope guidance also describes enforcement discretion for certain provisions while retaining predicate-rule obligations; teams should read both rather than treating this table as legal advice. Electronic-signature requirements extend beyond Section 11.10 and need separate assessment where applicable. [9] [8]

For AI investigations, we recommend recording the relevant model identifier, prompt-template version, retrieved source versions, tool actions, approvals, and final disposition, subject to privacy and retention policies. These are proposed engineering controls—not a claim that Part 11 explicitly lists those AI-specific fields. A fluent explanation is not a substitute for an execution record.

Comparing Platforms: Start with the Deployment Layer

Comparing a workplace assistant with an agent-development service or an application-native agent is not a like-for-like exercise. First decide whether you need a user workspace, a custom workflow platform, or capabilities embedded in an existing business application. Then compare specific plans, configurations, regions, and contracts.

Claude vs. ChatGPT for Life Sciences: Key Evaluation Criteria for Tech Leaders

Anthropic documents lifesciences connectors and skills for scientific and clinical workflows, including protocol drafting. OpenAI positions ChatGPT for Healthcare around evidence-supported assistance, institutional knowledge, and organizational controls. These are useful starting points, not independent demonstrations of superiority. [12] [13]

For a meaningful Claude vs. ChatGPT for life sciences comparison, use the same approved source material and tasks: retrieve supporting evidence, identify contradictions, draft a bounded summary, and decline an unsupported conclusion. Check citation accuracy, omissions, tool actions, and reviewer effort. Identify the exact model and configuration; a brand name does not specify an evaluation condition.

Distinguish a consumer account, an enterprise workspace, and an API-based application. Anthropic’s HIPAA-ready Enterprise documentation and OpenAI’s HIPAA eligibility documentation describe configuration and feature boundaries. A BAA is not automatically applicable to every feature or connected third-party service, and HIPAA arrangements do not establish GxP validation. Confirm the actual contract and approved feature set before using sensitive data. [14] [15]

Evaluating Microsoft Copilot and Azure AI Foundry for Pharma

Tech Leaders, CTOs, etc., searching for Microsoft Copilot / Azure AI Foundry for pharma should note Microsoft’s current developer-platform naming: Azure AI Foundry is now documented as Microsoft Foundry. It provides tools for building agents and working with models, evaluations, tracing, identity, and access controls. The organizational Copilot experience is a different surface, focused on employee assistance and organizational information. [16] [17]

Choose the evaluation path accordingly. For employee assistance, test whether information access respects user permissions. For a custom agent, evaluate the orchestration, connector authorization, evidence capture, and release controls. Check whether each selected feature is generally available or preview, available in your deployment region, and covered by the relevant terms. Microsoft’s enterprise data-protection documentation also identifies boundaries around web search and agents; do not assume all connected functions inherit identical protections. [17]

Evaluating AWS Bedrock Agents in GxP Environments

Amazon Bedrock Agents combines a model with instructions, action groups, and/or knowledge bases to orchestrate tasks. AWS’s guide to building agents in GxP environments discusses risk-based implementation and supporting infrastructure, including AgentCore capabilities. This is a build-and-govern path, not a ready-validated pharmaceutical application. [18] [19]

When assessing AWS Bedrock agents in GxP environments, ask the proposed delivery team to demonstrate the full path from user request to data retrieval, tool authorization, review, and final record. Require a responsibility matrix for configuration, validation, monitoring, incidents, and change control. Execution traces support investigation, but must be assessed for completeness, retention, and suitability in the actual workflow. AWS implementation guidance is not regulatory approval. [18]

Where Veeva Vault AI Agents Fit in Your Platform Evaluation?

Veeva Vault AI Agents are application-integrated capabilities. Vault documentation describes standard and custom agents with configurable context, actions, and tools, including document summarization, questions, translation, and version comparison. Availability and activation depend on the application and feature. [20]

For a Vault-based workflow, test permissions, source-version selection, action attribution, and approvals within that application. Ask which agents and actions are available in your licensed environment, how custom configurations are governed, and what evidence the vendor supplies versus what your organization must generate. Existing use of Vault does not establish that every new agent, prompt, or action is fit for your intended use.

These are shortlist hypotheses, not measured rankings. Test them against your use case rather than interpreting a platform category as a performance or compliance guarantee. Product availability, feature coverage, and contracts can change.

Choosing Agentic AI Services for Pharma Commercial Analytics

When evaluating agentic AI services for pharma commercial analytics, start with a measurable business question: explain a territory variance, reconcile account information, or prepare a field-team briefing. Avoid an open-ended mandate to “optimize sales” without defined inputs, constraints, and success criteria.

The best agentic analytics platforms for pharma sales analytics should be judged on the reliability of the complete analytical workflow. A persuasive narrative is not enough if the underlying query uses the wrong time period or denominator.

• Metric fidelity: Compare calculations with approved SQL or a governed business-intelligence model. Check units, time periods, denominators, and aggregation.
• Identity resolution: Test duplicate accounts, territory changes, and conflicting identifiers.
• Permission fidelity: Verify that responses and tool actions respect source-system access boundaries.
• Evidence quality: Require traceable data sources, refresh dates, and a clear distinction between observed patterns and suggested explanations.
• Action boundaries: Separate preparing an internal recommendation from changing CRM records or sending external communications.
• Business impact: Measure analyst time, correction effort, adoption, and outcomes against a baseline. Do not attribute sales changes to AI without a suitable evaluation design.

These are recommended procurement tests, not claims of demonstrated performance by a named vendor. Assess privacy, commercial, promotional, and pharmacovigilance implications with the relevant specialists when defining the actual workflow.

Measure Cost per Accepted Outcome, Not Just Cost per Token

Kapoor and colleagues’ research preprint, AI Agents That Matter, identifies shortcomings in agent evaluation, including narrow accuracy measures, weak holdout sets, cost neglect, and limited reproducibility. Their findings support jointly evaluating quality and cost; they do not demonstrate commercial ROI in pharma. [10]

A practical metric is:

Cost per accepted task = Total evaluation-period operating cost ÷ Tasks meeting predefined acceptance criteria.

Specify whether the numerator includes inference, orchestration, retries, monitoring, and reviewer time. Report setup and validation costs separately, then include them in a longer-term total-cost estimate. Never make a cheaper model look economical by excluding correction work.

Evaluating Validation Document Management Software and GxP Digital Archives

Validation document management software for pharma and a digital archive serve related but different buying needs. For this evaluation, treat document management as control of active authoring, revision, review, approval, and traceability; treat archiving as preservation and retrieval over the required lifecycle. One product may support both, but buyers should test both functions.

For GMP systems, Annex 11’s 2011 text addresses traceable user requirements, migration checks, backup restoration, periodic evaluation, and archiving. Section 17 specifically calls for checks of archived data accessibility, readability, and integrity, and testing retrieval when relevant system changes occur. [3]

Instead of selecting the best GxP digital archive vendors from a generic ranking, require demonstrations using representative records:

• Retrieve a record with its relevant metadata, history, and associated approvals.
• Show how source records and AI-generated derivatives remain distinguishable.
• Demonstrate retention controls, authorized disposition, and any required holds.
• Restore a backup and verify the restored data, rather than showing only that backups run.
• Export records and their context in usable formats for inspection or migration.
• Explain how access, readability, and retrieval are maintained after upgrades or contract termination.

Do not let an AI summary become the only surviving representation of a required record. The European Commission’s consultation materials for revised Chapter 4, Annex 11, and a new AI Annex 22 also warrant monitoring. The linked documents are identified as drafts; this article does not treat their proposed provisions as binding. [11]

A Vendor Scorecard for Pharma AI Platform Selection

Use a weighted scorecard to compare AI platforms for pharmaceutical validation after agreeing on the workflow. The following weights are an illustrative Infiligence editorial framework—not a regulatory standard, a validated instrument, or measured vendor scores.

Score each criterion from 0 to 5 using a defined rubric: 0 means absent or unproven; 3 means demonstrated with material limitations; 5 means demonstrated against your agreed criteria. Calculate the total as the sum of weight × score ÷ 5, using weights expressed as percentage points, for a maximum of 100. Set the remaining rubric levels before testing and keep the evidence behind every score.

Apply mandatory gates before scoring. A high average should never compensate for an unacceptable data-use contract, inability to enforce a required approval, inaccessible required records, or failure on a safety-critical acceptance criterion. For a commercial analytics workflow, adjust weights deliberately rather than copying the validation scorecard unchanged.

What to Measure in a Proof of Value?

• Task acceptance rate: The proportion meeting all predefined criteria.
• Critical error rate: The proportion with errors above an agreed severity threshold.
• Evidence accuracy: Whether cited sources actually support the claims and use the correct versions.
• Action safety: Unauthorized or incorrect tool actions, including approval bypass attempts.
• Repeatability: Variability across runs, users, input formats, and source updates.
• Human effort: Review time, correction time, and escalation burden.
• Operational performance: End-to-end latency, failures, recovery, and cost per accepted outcome.

Disclose the number of tasks and repetitions, configuration, exclusions, and uncertainty. If comparing platforms as sold, report their default configurations and total costs. If comparing models under matched conditions, hold the surrounding tools and evidence access constant. Those are different experiments; do not combine their conclusions into a single “best model” claim.

From Platform Selection to a Governed Implementation

Once a candidate passes evaluation, progress through controlled stages: define the intended use; assess data and integrations; establish acceptance criteria; test in a segregated environment; run a limited, reviewed pilot; and expand only after resolving failures and assigning operational ownership. Where appropriate, begin in read-only or shadow mode before enabling write actions.

Keep the validation boundary visible as the system changes. A new connector, broader permission, revised retrieval pipeline, or model update may change what the earlier evidence supports. Plan reassessment around the impact of the change rather than assuming that a successful pilot permanently establishes reliability.

At Infiligence, our perspective is that platform engineering should connect infrastructure, integration, security, testing, monitoring, and human oversight into a reusable foundation. The value is not to remove quality accountability, but to make the supporting controls and evidence easier to maintain across initiatives.

Choosing an agentic AI platform for pharma GxP validation is therefore an engineering and operating-model decision as much as a procurement decision. Choose the workflow first, define the evidence second, and select the platform that can meet both.

Frequently Asked Questions

What Is the Best Agentic AI Platform for Pharma?

There is no winner established by this guide. Evaluate the specific product, deployment, contracts, integrations, and evidence against your intended use. A platform suited to internal research assistance may not be the best fit for controlled quality workflows or sales analytics.

Can AI Automate GxP Validation?

AI may assist with drafting, mapping, or reviewing evidence, but those outputs still need evaluation under the organization’s defined process. Distinguish automating a documentation task from establishing that the resulting system is fit for its intended use. Annex 11 links validation evidence to requirements and risk assessment, not the mere production of documents. [3]

Does Every Pharma AI Application Fall Under Part 11?

No. Determine applicability from the relevant electronic records, electronic signatures, predicate rules, and actual use. FDA’s scope guidance recommends documenting those decisions. [8]

What Should a GxP Company Ask an AI Supplier?

Ask for a precise responsibility split, evidence of the configured workflow’s performance, supplier quality information, contractual data protections, controlled change processes, and usable records. Require demonstrations, not only policy statements or product labels.

Should Commercial Analytics and Validation Use the Same AI Platform?

Only if it meets each workflow’s independently defined requirements. A shared foundation may reduce duplication, but permissions, evidence, review steps, and acceptance criteria should be assessed separately.

Sources and Research

Research findings below inform evaluation design; they do not certify any platform. Historical studies are identified by publication year. Product capabilities should be rechecked during procurement. This article is educational, not legal or regulatory advice; obtain quality and regulatory review before applying it to a specific system.

1. FDA and EMA. Guiding Principles of Good AI Practice in Drug Development (2026).
2. MHRA. MHRA’s GXP data integrity guide published (2018); guidance and scope notes, including the GLP-specific OECD precedence note.
3. European Commission. EU GMP Annex 11: Computerised Systems (2011 text).
4. FDA. Considerations for the Use of Artificial Intelligence To Support Regulatory Decision-Making for Drug and Biological Products (January 2025; draft guidance).
5. Wornow M. et al. The shaky foundations of large language models and foundation models for electronic health records. npj Digital Medicine 6, 135 (2023). Peer-reviewed narrative review. DOI: 10.1038/s41746-023-00879-8.
6. Liu N. F. et al. Lost in the Middle: How Language Models Use Long Contexts. Transactions of the Association for Computational Linguistics 12, 157–173 (2024). Peer-reviewed research. DOI: 10.1162/tacl_a_00638.
7. Kim Y. et al. Towards a Science of Scaling Agent Systems (2025, version 1). Research preprint, not presented here as peer-reviewed evidence.
8. FDA. Part 11, Electronic Records; Electronic Signatures—Scope and Application. Nonbinding guidance explaining applicability and enforcement policy.
9. 21 CFR § 11.10: Controls for closed systems, regulatory text reproduced by Cornell Legal Information Institute.
10. Kapoor S. et al. AI Agents That Matter (2024). Cited here as a research preprint; see also the authors’ evaluation findings.
11. European Commission. Consultation: revised Chapter 4, Annex 11, and new Annex 22. Linked draft proposals are not treated here as binding requirements.
12. Anthropic. Healthcare and life-sciences capabilities. Official product announcement; vendor-reported capabilities.
13. OpenAI. OpenAI for Healthcare. Official product announcement; vendor-reported capabilities.
14. Anthropic. HIPAA-ready Enterprise plans. Configuration and scope documentation.
15. OpenAI. HIPAA-eligible products and functionality. Product and feature coverage documentation.
16. Microsoft. What is Microsoft Foundry? Current naming and developer-platform documentation.
17. Microsoft. Enterprise data protection in organizational Copilot. Data and connected-feature scope documentation.
18. AWS. A guide to building AI agents in GxP environments (2025). Vendor implementation guidance, not a regulator’s endorsement.
19. AWS. How Amazon Bedrock Agents works. Official technical documentation.
20. Veeva. Vault AI Agents. Official application documentation.